298 related articles for article (PubMed ID: 22917641)
1. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R
Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer.
Gigliotti CL; Minelli R; Cavalli R; Occhipinti S; Barrera G; Pizzimenti S; Cappellano G; Boggio E; Conti L; Fantozzi R; Giovarelli M; Trotta F; Dianzani U; Dianzani C
J Biomed Nanotechnol; 2016 Jan; 12(1):114-27. PubMed ID: 27301177
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Cirpanli Y; Bilensoy E; Lale Doğan A; Caliş S
Eur J Pharm Biopharm; 2009 Sep; 73(1):82-9. PubMed ID: 19442723
[TBL] [Abstract][Full Text] [Related]
4. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
6. Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.
Nekkanti V; Karatgi P; Paruchuri S; Pillai R
Drug Deliv; 2011 May; 18(4):294-303. PubMed ID: 21214430
[TBL] [Abstract][Full Text] [Related]
7. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
Huang Q; Wang L; Lu W
Eur J Med Chem; 2013 May; 63():746-57. PubMed ID: 23578545
[TBL] [Abstract][Full Text] [Related]
8. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
9. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
10. Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.
Kim C; Kim S; Oh WK; Choi M; Jang J
Chemistry; 2012 Apr; 18(16):4902-8. PubMed ID: 22422377
[TBL] [Abstract][Full Text] [Related]
11. Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization.
Ünal S; Aktaş Y; Benito JM; Bilensoy E
Int J Pharm; 2020 Jun; 584():119468. PubMed ID: 32470483
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
Cırpanlı Y; Allard E; Passirani C; Bilensoy E; Lemaire L; Calış S; Benoit JP
Int J Pharm; 2011 Jan; 403(1-2):201-6. PubMed ID: 20951783
[TBL] [Abstract][Full Text] [Related]
14. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
15. Fabrication of nanomicelle with enhanced solubility and stability of camptothecin based on alpha,beta-poly[(N-carboxybutyl)-L-aspartamide]-camptothecin conjugate.
Fan N; Duan K; Wang C; Liu S; Luo S; Yu J; Huang J; Li Y; Wang D
Colloids Surf B Biointerfaces; 2010 Feb; 75(2):543-9. PubMed ID: 19846282
[TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor study of camptothecin nanocrystals.
Zhang H; Hollis CP; Zhang Q; Li T
Int J Pharm; 2011 Aug; 415(1-2):293-300. PubMed ID: 21679755
[TBL] [Abstract][Full Text] [Related]
17. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
19. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
